title: Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.
abstract: Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo.
authors.affiliation: Département d'Hématologie, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, Montpellier, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.affiliation: Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France. Inserm U917, Université de Rennes 1, Rennes, France.
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, Stanford, California. kohrt@stanford.edu.
authors.forename: Holbrook E
authors.initials: HE
authors.lastname: Kohrt
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D017452:Receptors, IgG; D000069283:Rituximab